HF
CODX

HRT Financial’s Co-Diagnostics CODX Stock Holding History

HRT Financial’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,976
Closed -$51K – 3281
2025
Q3 		$51K Buy
4,976
+4,533
+1,023% +$42.2K ﹤0.01% 2602
2025
Q2 		$3K Sell
443
-32
-7% -$299 ﹤0.01% 2494
2025
Q1 		$4K Buy
+475
New +$9.08K ﹤0.01% 2412
2023
Q2 		– Sell
-417
Closed -$18K – 2576
2023
Q1 		$18K Buy
417
+21
+5% +$1.68K ﹤0.01% 2190
2022
Q4 		$29K Buy
+396
New +$37.1K ﹤0.01% 2146
2022
Q1 		– Sell
-947
Closed -$253K – 3208
2021
Q4 		$253K Sell
947
-764
-45% -$200K ﹤0.01% 2375
2021
Q3 		$499K Sell
1,711
-864
-34% -$252K ﹤0.01% 1981
2021
Q2 		$637K Buy
+2,575
New +$662K 0.01% 1556

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAG
Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HRT Financial's CODX Position: Q4 2025 in Review

HRT Financial sold out of Co-Diagnostics (CODX) in Q4 2025, closing a stake of 4,976 shares — an estimated $51K sold.

HRT Financial first reported a position in CODX in Q2 2021 and held it in 8 quarters. The position peaked at $637K in Q2 2021. 30 funds tracked by Wall St. Rank hold CODX as of Q4 2025.

  • HRT Financial reported no remaining Co-Diagnostics position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 4,976 Co-Diagnostics shares in Q4 2025, an estimated $51K.
  • HRT Financial first reported a position in Co-Diagnostics in Q2 2021 and held it in 8 quarters.
  • HRT Financial's Co-Diagnostics position peaked at $637K in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.